Skip Navigation Links.
Collapse <span class="m110 colortj mt20 fontw700">Volume 12 (2024)</span>Volume 12 (2024)
Collapse <span class="m110 colortj mt20 fontw700">Volume 11 (2023)</span>Volume 11 (2023)
Collapse <span class="m110 colortj mt20 fontw700">Volume 10 (2022)</span>Volume 10 (2022)
Collapse <span class="m110 colortj mt20 fontw700">Volume 9 (2021)</span>Volume 9 (2021)
Collapse <span class="m110 colortj mt20 fontw700">Volume 8 (2020)</span>Volume 8 (2020)
Collapse <span class="m110 colortj mt20 fontw700">Volume 7 (2019)</span>Volume 7 (2019)
Collapse <span class="m110 colortj mt20 fontw700">Volume 6 (2018)</span>Volume 6 (2018)
Collapse <span class="m110 colortj mt20 fontw700">Volume 5 (2017)</span>Volume 5 (2017)
Collapse <span class="m110 colortj mt20 fontw700">Volume 4 (2016)</span>Volume 4 (2016)
Collapse <span class="m110 colortj mt20 fontw700">Volume 3 (2015)</span>Volume 3 (2015)
Collapse <span class="m110 colortj mt20 fontw700">Volume 2 (2014)</span>Volume 2 (2014)
Collapse <span class="m110 colortj mt20 fontw700">Volume 1 (2013)</span>Volume 1 (2013)
American Journal of Medical Case Reports. 2021, 9(1), 24-31
DOI: 10.12691/AJMCR-9-1-8
Review Article

Gastrointestinal Symptoms and Immune Response in COVID 19 - Review of a Cat and Mouse Game Theory

Abhilash Haridas1, and Payal Mukker2

1Department of Gastroenterology, Sree Gokulam Medical College & Sree Gokulam GG Hospital, Trivandrum, India

2Department of Medicine, Sree Gokulam Medical College & Gokulam Covid Care Center (GCC), Trivandrum, India

Pub. Date: October 27, 2020
Full Text PDF

Cite this paper

Abhilash Haridas and Payal Mukker. Gastrointestinal Symptoms and Immune Response in COVID 19 - Review of a Cat and Mouse Game Theory. American Journal of Medical Case Reports. 2021; 9(1):24-31. doi: 10.12691/AJMCR-9-1-8

Abstract

Gastrointestinal (GI) symptoms are not uncommon in COVID-19 infection. The varied symptomatology and severity of GI symptoms are related to the difference in host viral interaction. We have reviewed the GI manifestations of these patients and noted that three subgroups exist.A group with self-limited GI disease, a group with predominant GI manifestations and group with severe GI disease. A review of the immune response in the different groups with GI manifestations has been done and illustrated by a cat and mouse game theory. In self-limited GI disease, there is early active innate immunity with type I interferon response and followed by an efficient adaptive immune response causing viral clearance. In patients with predominant GI symptoms, viral factors override innate immune mechanisms and cause delayed and weak innate antiviral response. The subsequential adaptive response is a "mishit" response with mucosal injury and GI symptoms. In the later part of this infection, a resurgent adaptive immunity induction can occur, causing persistent fecal shedding followed by viral clearance. In severe disease, there is heightened dysregulation of the adaptive immune response leading to cytokine storm and severe complications like pyroptosis, endothelitis, and hemophagocytic lymphohistiocytosis.

Keywords

COVID-19, SARS CoV-2, gastrointestinal symptoms, innate immunity, adaptive immunity, cytokine storm

Copyright

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]  WHO COVID-19 situation report-172 on 10 July 2020.
 
[2]  Guo YR, Cao QD, Hong ZS, et al. The origin, transmission, and clinical therapies on coronavirus disease 2019(COVID-19) outbreak-an update on the status. Military Medical Research.2020; 7(1): 11.
 
[3]  Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) From publicly reported confirmed cases: estimation and application. Annals of Internal Medicine. 2020; 172: 577-582.
 
[4]  Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-1069.
 
[5]  Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine. 2020; 382: 1708-1720.
 
[6]  Wong, S. H., Lui, R. N. S., and Sung, J. J. Y. Covid‐19 and the digestive system. Journal of Gastroenterology and Hepatology 2020. 35: 744-748.
 
[7]  Li, M., Li, L., Zhang, Y. et al. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infectious Disease of Poverty. 2020, 9: 45.
 
[8]  Nikolich-Zugich, J., Knox, K. S., Rios, C. T., Natt, B., Bhattacharya, D., & Fain, M. J. SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes. GeroScience.2020, 42(2), 505-514.
 
[9]  La Vignera, S.; Cannarella, R.; Condorelli, R.A.; Torre, F.; Aversa, A.; Calogero, A.E. Sex-Specific SARS-CoV-2 mortality: among hormone-modulated ACE2 expression, risk of venous thromboembolism and hypovitaminosis D. International Journal of Molecular Science. 2020, 21, 2948.
 
[10]  Yaqinuddin A, Kashir J. Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Chloroquine, and antiviral agents. Medical Hypotheses. 2020; 140: 109777.
 
[11]  Castilla J, Sola I, Enjuanes L. Interference of coronavirus infection by expression of immunoglobulin G (IgG) or IgA virus neutralizing antibodies. Journal of Virology.1997; 71(1): 5251-58.
 
[12]  Okba NM, Muller MA, Li W, et al. SARS-CoV-2 specific antibody responses in COVID-19 patients. 2020. medRxiv preprint.
 
[13]  Guo L, Ren L, Yang S, et al. Profiling early humoral response to diagnose novel coronavirus disease 461 (COVID-19). Clinical Infectious Diseases, 2020.
 
[14]  Mak JWY, Chan FKL, Ng SC, et al. Probiotics and COVID-19: one size does not fit all. Lancet Gastroenterology Hepatology 2020.
 
[15]  Feng, Z.; Wang, Y.; Qi, W. The small intestine, an underestimated site of SARS-CoV-2 infection: From red queen effect to probiotics. 2020.
 
[16]  Thevarajan I, Nguyen THO, Koutsakos M, et al. Breadth of concomitant immune responses prior to patient recovery: a case report of nonsevere COVID-19. Nature Medicine. 2020; 26(4): 453-455.
 
[17]  Pan L, Mu M, Yang P, et al. Clinical characteristics of COVID-19 in Patients with digestive symptoms in Hubei, China: A descriptive, cross-sectional, multicenter study. American Journal of Gastroenterology.2020; 115(5):766-773.
 
[18]  Jin X, Lian JS, Hu JH, et al. Epidemiological, clinical, and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020; 69(6): 1002-1009.
 
[19]  Zhao D, Yao F, Wang L, et al. A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias. Clinical Infectious Disease. 2020; 71(15): 756-761.
 
[20]  Esposito G, Pesce M, Seguella L, Sanseverino W, Lu J, Sarnelli G. Can the enteric nervous system be an alternative entrance door in SARS-CoV2 neuroinvasion? Brain Behaviour Immunity. 2020; S0889-1591(20)30644-9.
 
[21]  Yu IT, Li Y, Wong TW et al. Evidence of airborne transmission of the severe acute respiratory syndrome virus. New England Journal of Medicine. 2004; 350:1731-9.
 
[22]  Holshue M. L., DeBolt C., Lindquist S., Lofy K. H., Wiesman J., Bruce H. et al. First case of 2019 novel coronavirus in the United States. New England Journal of Medicine.2020; 382, 929-936.
 
[23]  Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology. 2020; 158(6):1831-1833.e3.
 
[24]  Wang W, Xu Y, Gao R et al. Detection of SARS-CoV-2 in different clinical specimens. JAMA. 2020.
 
[25]  Chen, Y, Chen, L, Deng, Q, et al. The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients. Journal of Medical Virology. 2020; 92: 833-840.
 
[26]  Zhang H, Li HB, Lyu JR, et al. Specific ACE2 expression in small intestinal enterocytes may cause gastrointestinal symptoms and injury after 2019-nCoV infection. International Journal of Infectious Disease.2020; 96: 19-24.
 
[27]  McCullough, K.C., Sharma, R.: Dendritic cell endocytosis essential for viruses and vaccines. Biology of Myelomonocytic Cells, 2017; pp. 99-128.
 
[28]  Gutierrez L, Beckford J, Alachkar H. Deciphering the TCR Repertoire to Solve the COVID-19 Mystery. Trends in Pharmacological Sciences. 2020; S0165-6147(20)30130-9.
 
[29]  Wang, Fuzhou et al. An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development. Medical science monitor: International medical journal of experimental and clinical research.2020; vol. 26 e924700.
 
[30]  Hashimoto T, Perlot T, Rehman A, et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature. 2012; 487(7408): 477-481.
 
[31]  Belladonna ML, Orabona C. Potential Benefits of Tryptophan Metabolism to the Efficacy of Tocilizumab in COVID-19. Frontiers in Pharmacology. 2020; 11: 959.
 
[32]  Tan, L., Wang, Q., Zhang, D. et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduction and Targeted Therapy.2020; 5(1), 33.
 
[33]  Azkur, A.K., Akdis, M., Azkur, D., Sokolowska, M., van de Veen, W., Brüggen, M.-C., O'Mahony, L., Gao, Y., Nadeau, K. and Akdis, C.A. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.
 
[34]  Daniel Blanco-Melo, Benjamin E. Nilsson-Payant, Wen-Chun Liu, Skyler Uhl, Daisy Hoagland, Rasmus Møller, Tristan X. Jordan, Kohei Oishi, Maryline Panis, David Sachs, Taia T. Wang, Robert E. Schwartz, Jean K. Lim, Randy A. Albrecht, Benjamin R. tenOever.Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19.Cell,2020;181:5:1036-1045.e9.
 
[35]  Mali SN, Pratapb AP, Thorat BR. The Rise of New Coronavirus Infection (COVID-19): A Recent Update and Potential Therapeutic Candidates. Eurasian Journal of Medical Oncology. 2020; 4(1): 35-41.
 
[36]  Zsuzsanna Varga, Andreas J Flammer, Peter Steiger, Martina Haberecker, Rea Andermatt, Annelies S Zinkernagel, Mandeep R Mehra, Reto A Schuepbach, Frank Ruschitzka, Holger Moch. Endothelial cell infection and endotheliitis in COVID-19. The Lancet, 2020; 395(10234): 1417-1418.
 
[37]  Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: Immunology and treatment options. Clinical Immunology. 2020; 215: 108448.